ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

COS Collagen Solutions Plc

6.625
0.00 (0.00%)
19 Mar 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Collagen Solutions Plc LSE:COS London Ordinary Share GB00B94T6Y14 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 6.625 6.25 7.00 - 0.00 00:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Collagen Solutions Share Discussion Threads

Showing 376 to 398 of 850 messages
Chat Pages: Latest  22  21  20  19  18  17  16  15  14  13  12  11  Older
DateSubjectAuthorDiscuss
01/12/2015
13:30
Financially, Collagen Solutions made a big leap with revenues up more than ten-fold year on year at £1.46mln in the six months to September 30.

The underlying loss (LBITDA) of £79,376 reveals the group is approaching break-even. The figure has narrowed from over £522,000 previously. The loss before tax was also down sharply at £356,537.

Importantly, the business still in a very healthy position with £3.1mln in the bank.

jacobjohn7
01/12/2015
13:28
Collagen Solutions' interims chart a period of significant progress
Share
08:02 01 Dec 2015
The company is is making headway both operationally and financially.
Collagen Solutions' interims chart a period of significant progress
Recent acquisition ChondroMimetic provides collagen-based implant for treatment of small cartilage and underlying bone defects.
Collagen Solutions (LON:COS) interims revealed it is making headway both operationally and financially.

The company expanded its expertise in September with the acquisition of ChondroMimetic, which provides collagen-based implant for treatment of small cartilage and underlying bone defects.

It also strengthened the board with the appointment of chief operating officer Tom Hyland and secured a significant supply deal with Histogenics Corp during the period under review.

Other highlights included the granting of a patent for processing new biomaterial for heart patients, while its experts also joined teams carrying out pioneering work in arthritis and Parkinson’s disease.

Financially, Collagen Solutions made a big leap with revenues up more than ten-fold year on year at £1.46mln in the six months to September 30.

The underlying loss (LBITDA) of £79,376 reveals the group is approaching break-even. The figure has narrowed from over £522,000 previously. The loss before tax was also down sharply at £356,537.

Importantly, the business still in a very healthy position with £3.1mln in the bank.

Chief executive Stewart White told investors: “The Collagen Solutions value proposition received further external validation within the period via supply agreements signed with new customers, additional FDA approval of customers' products and our participation in cutting edge research programmes in new clinical areas such as the treatment for Parkinson's disease.

“These achievements have been possible through the hard work of our colleagues across the globe."

jacobjohn7
01/12/2015
12:31
done dummy sell for decent qty and the market makers certainly want shares... good sign
jacobjohn7
01/12/2015
12:27
Having read that growth is very impressive at this stage and well within forecasts and should be headlined by financial media tomorrow.

Cash balance is impressive, and opportunities are growing.
I'm happy with it, and content to let the story unfold, another contract win RNS would get us bouncing along merrily though.

Building an facility extension for a specific company is very exciting, as well as building production capacity for the future it makes you think how big a company and revenue potential they are doing this for.

This is as good as could have been expected at this stage... and the forecast of cash flow positivity by end of the year would be very impressive... IMO this will snowball quite quickly once we gain that traction.

jacobjohn7
01/12/2015
12:12
-- Revenue and other income increased to GBP1,460,218 (H1 2014: GBP143,213)
jacobjohn7
01/12/2015
12:05
Collagen Solutions PLC

01 December 2015

1 December 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Half Yearly Report

Interim Results for the six months ended 30 September 2015

Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, announces results for the six months ended 30 September 2015.

Financial Highlights

-- Revenue and other income increased to GBP1,460,218 (H1 2014: GBP143,213)
-- LBITDA- GBP(79,376) (H1 2014: GBP(522,144)
-- Pre-tax loss - GBP(356,537) (H1 2014: GBP(560,831)
-- Basic loss per share - (0.26)p (H1 2014: (0.88)p)
-- Net cash balances of GBP3,104,230 at 30 September 2015 (31 March 2015 : GBP3,391,356)
Operational Highlights

-- Acquisition of assets and exclusive world licence for ChondroMimetic, a collagen based implant for treatment of small osteochondral (cartilage and underlying bone) defects, together with related IP for use in other clinical applications.

-- Management team strengthened by appointment of Chief Operating Officer
-- Supply agreement signed with Histogenics Corporation
-- New US patent granted for processing of new biomaterial for heart patients
-- Partnership with UCL and Oxford MEStar in grant award from Arthritis Research UK
-- Joined EUR4 million Horizon 2020 grant funded research project to develop novel treatments for Parkinson's disease

Post Period End

-- R&D headcount increased in San Jose to further develop new high value collagen products
-- Management team strengthened by appointment of Chief Business Officer in USA
Dr Stewart White, Chief Executive Officer of Collagen Solutions, commented: "I am pleased to report that trading for the period demonstrated a significant increase in revenue with reduction in LBITDA compared with the same period in 2014, whilst maintaining a healthy cash position. The Collagen Solutions value proposition received further external validation within the period via supply agreements signed with new customers, additional FDA approval of customers' products and our participation in cutting edge research programmes in new clinical areas such as the treatment for Parkinson's disease. These achievements have been possible through the hard work of our colleagues across the globe."


Collagen Solutions Plc
David Evans, Chairman Tel: 07740 084 452
Stewart White, CEO / Tel: 0141 648 9100
Gill Black, CFO

Panmure Gordon (Nominated
Adviser and Broker)
Rob Naylor (Corporate Finance) Tel: 0207 886 2714
Maisie Atkinson (Corporate Tel: 0207 886 2905
Sales)

Walbrook PR Ltd Tel: 020 7933 8780 or
collagen@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001


Chairman's Statement

I am pleased to present Collagen Solutions' interim results for the six month period ended 30 September 2015. During the period, we have made further progress in increasing revenue from new and existing customers and products across the Group.

The strategic objective is to build a significant global biomaterials business by assisting customers in expediting the transition of their products from development through to manufacture by the provision of cost effective, functional medical grade collagen materials and devices across a range of clinical indications, for the ultimate benefit of patients by providing effective and affordable treatments.

Overview

During this six month period, revenue has increased by 141% over the full year revenue for 2014/15. Revenue growth has come from both our material supply and contract manufacturing activities with the acquisition of Southern Lights Biomaterials making a significant contribution. We have continued to invest in our R&D teams, senior management team, internally generated IP; such as the new US patent granted in May, and our manufacturing facilities in the UK and New Zealand. We have also taken the opportunity to acquire the assets and exclusive worldwide IP licence to the ChondroMimetic product, a collagen based implant for treatment of cartilage and underlying bone defects. This IP family and platform technology also gives opportunities to develop a pipeline of additional products from the platform technologies for further clinical indications which we believe have the potential to create long-term shareholder value.

The senior management teams in Glasgow, San Jose and New Zealand have been successfully integrated and are working effectively as a cohesive unit to execute our strategic plan.

We have set ourselves a target by 2020 to create a biomaterials business with a value of GBP100 million, through a combination of organic growth, exploitation of licensed IP and appropriate acquisitions. In order to achieve this we have been putting in place the necessary resources to make this happen.

Results

The Group's results for the six months ended 30 September 2015 are set out in the Consolidated Statement of Comprehensive Income. Revenue (including other income) for the first six months was up significantly to GBP1,460,218 (2014: GBP143,213). Administrative expenses were GBP898,284 (2014: GBP467,672), selling and marketing costs were GBP266,300 (2014: GBP161,171), LBITDA for the first six months was (GBP79,376) (2014: (GBP522,144)), and the loss per share reduced to (0.26)p (2014: (0.88)p).

Net cash generated from operations during the period was GBP35,444. The Group's cash balances at 30 September 2015 were GBP3,104,230 (31 March 2015: GBP3,391,356).

Board and management

The team is working together well as a cohesive unit under Stewart's leadership, with the Scientific Advisory Board providing important input into our product development strategies through the stage gate process. At the start of the period, we appointed Tom Hyland as Chief Operating Officer. Tom has a wealth of knowledge and experience in collagen chemistry and GMP manufacturing. More recently we are delighted to welcome Jamal Rushdy as Chief Business Officer. He has over 20 years' experience in the medical device arena, specifically within two mid-size high growth public companies and three successful start-ups. Jamal has an impressive track record of building businesses with successful exits and transforming organisations through integration and performance improvement.

The Board and the employees of Collagen Solutions are deeply saddened by the recent death, after a short illness, of our Non-Executive Director, Dr Kevin Wilson. Kevin was both a close friend and colleague of mine of many years standing and he played a pivotal role in the formation of this Company. His humanity, wit, creativity and enthusiasm will be sadly missed. He never sought the limelight and I often felt he never got the credit he deserved from others outside his close circle of friends. Kevin's passing leaves a gap in our Board that will be enormously difficult to fill and we will update you in due course in this regard.

As a consequence of this, I will be assuming the role of Chairman of the Audit and Risk Committee.

Current Outlook

As I look forward in terms of the rest of this financial year and beyond I am encouraged by our continued progress and the overall direction of travel. As ever my desire for greater momentum and being able to execute the opportunities we have in a timely fashion remains a high priority.

The overall positive background and the ability to secure new contracts gives me comfort that the second half of the year will see further growth in our revenues. Our pipeline of opportunities continues to remain robust but with a degree of uncertainty prevailing regarding the exact timing of contract execution.

We have yet to reach a critical mass of manufactured product and consistent cash flow positivity. We anticipate, excluding investing activities we will be operationally cash positive by the year end, if not for the year as a whole.

There are a number of more significant growth opportunities which may crystallise in 2016;

- The building of a new facility in New Zealand to accommodate a specific customer requirement;

- The establishment of a joint-venture in China in order to work in the Chinese market with the right partner so that our products can service particular market segments cost effectively; and

- The commercialisation of the IP from ChondroMimetic, a treasure trove of value enhancing opportunities. This however will require its own dedicated management team if we are to retain our focus in our core business.

We continue to build our Company and its infrastructure in a relatively low risk manner by adopting a portfolio approach in a multi-product/customer/sector business model which monetises the embedded value in the business whilst enabling us to move up the value chain.

Thank you for your support

David E Evans

Chairman

1 December 2015

Collagen Solutions Plc

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

(MORE TO FOLLOW) Dow Jones Newswires

December 01, 2015 02:00 ET (07:00 GMT)

For the six months ended 30 September 2015

jacobjohn7
01/12/2015
12:04
FLASH: Collagen Solutions losses narrow

1 December 2015 | 07:26am
StockMarketWire.com -
- See more at: hxxp://www.stockmarketwire.com/article/5164595/FLASH-Collagen-Solutions-losses-narrow.html#sthash.pZCgrW0k.dpuf

jacobjohn7
01/12/2015
09:50
Building a new facility in N.Z. and adding to the existing management team will mean more expenditure. Meanwhile the long term chart in the header doesn't paint a very good picture and it's all very well the company saying their objective is to make this into a £100 million company by 2020, but existing long term shareholders, like myself, may be thinking they would be better off having their money in a bank account earning zero interest. imo
doodlebug4
01/12/2015
08:04
I rather like the tone and realism in the Chairman's statement, but there is clearly a big opportunity for this company. Cashflow breakeven by year end would be excellent. I do wonder whether the new facility in NZ, if needed, will require an additional fund raising in due course.
18bt
30/11/2015
13:29
Half year results tomorrow jacobjohn, so we will soon find out the answer to that.
doodlebug4
26/11/2015
10:28
Am i right in my thinking that the late payments that didnt make it onto previous results will appear on the interims 2nd December. .. and thus more chance of over achieving ☺
jacobjohn7
20/11/2015
15:33
RIP, Kevin Wilson
doodlebug4
20/11/2015
11:42
quite right.. been trading between 8-13p range up and down think this will be one of the best buying/adding points in last year...
Added £4k yesterday have a bit more dry powder but want momentum upwards now...

jacobjohn7
20/11/2015
11:39
The markets like a 'bargain' and so do the shareholders.:-)
doodlebug4
20/11/2015
11:25
Interesting article that.. the markets always like a 'bargain' and not overpaying for acquisitions... and so does the bottom line... ;o)
jacobjohn7
18/11/2015
15:24
Positive noises and revenue streams building up... but have to remember the fact that the company is forward thinking aquisition wise to put the whole thing in place to move on from. Its not pie in the sky either with fda approvals etc and proven but 'youthful' market for collagen based products... which is why im in i believe in the product. I personally think theyre striving to be a nice easy one stop shop aquisition for a big fish...
jacobjohn7
18/11/2015
14:48
Opinion on results - I will be looking at the obvious figures i.e., revenue and other income and pre-tax losses and also what Stewart White has to say in his statement. It is all very well saying that that the aim is to attain a valuation of £100 Million by 2020, but there comes a point where we need a realistic justification for that valuation. This is what he said in July when the Final Results were announced;

Dr Stewart White, Chief Executive Officer of Collagen Solutions, commented:
"I believe the Collagen Solutions Group is now an industry-recognised global force in the provision of value-added medical grade collagen biomaterials. The acquisition of Southern Lights Biomaterials cements our position by bringing an impressive customer base, providing surety of supply and commercial experience in the Asian markets. The Group now has a significant number of commercial opportunities to add to its already de-risked business model.

Our aim of attaining a valuation of £100 Million by 2020 is certainly closer not only due to M&A activities, but also through the normal course of our business, evidenced by the customer-related announcements we have made in the period. The assessment and plans for commercialisation of our own, and licensed-in IP continues, with the benefit of potential channels to market via an interested and existing customer base and network with which to partner."

doodlebug4
18/11/2015
13:47
Opinion on results? Think we will move within this trading range till then
jacobjohn7
18/11/2015
12:37
I agree, I've been holding these for quite some time now and look forward to the results on 1st December.
doodlebug4
18/11/2015
12:27
I have genuine belief that cos is ripe for being swallowed up as the story unfolds ..
jacobjohn7
18/11/2015
12:23
Added this morning (44,587) been bouncing about 8-13p for a year.. positive appointment with proven track record... and good buy/top up opportunity as we start an upwards trend
jacobjohn7
03/11/2015
08:42
RNS Number : 2810E

Collagen Solutions PLC

03 November 2015

Collagen Solutions Plc

(the "Company" or the "Group")

Notice of Half Year Results

Analyst Briefing

The Board of Collagen Solutions plc (AIM: COS), the developer and manufacturer of medical grade collagen components for use in regenerative medicine, medical devices and in-vitro diagnostics, will announce their unaudited interim results for the six months ending 30 September 2015 on Tuesday, 1 December 2015.

A briefing for analysts will take place at Walbrook PR, 4 Lombard Street, London EC3V 9HD at 9.30am on Tuesday 1 December 2015.

If you would like to register to attend the briefing, or require further information, please contact Walbrook PR on 020 7933 8780 or email collagen@walbrookpr.com.

doodlebug4
21/10/2015
12:54
Half yearly trading statement due in a few weeks time.
doodlebug4
Chat Pages: Latest  22  21  20  19  18  17  16  15  14  13  12  11  Older

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: +44 (0) 203 8794 460 | support@advfn.com